We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Bilirubin Improves Risk Prediction of Cardiovascular Death

By LabMedica International staff writers
Posted on 07 Jan 2019
Print article
Image: The Hitachi 7600 chemistry analyzer (Photo courtesy of Hitachi).
Image: The Hitachi 7600 chemistry analyzer (Photo courtesy of Hitachi).
Diabetes is one of the most prevalent disorders worldwide and cardiovascular (CV) disease is the leading cause of mortality and morbidity in diabetic patients. Therefore, improvements in risk prevention and adequate treatment are needed in these high-risk subjects.

Previous studies have shown that elevated serum bilirubin concentrations might protect against atherosclerosis, yet it remains unclear whether higher serum bilirubin concentrations work in favor of the cardiovascular system in patients with type 2 diabetes.

A team of scientists led by those at the National Yang-Ming University (Taipei, Taiwan, ROC) enrolled 2,936 subjects with type 2 diabetes (1,009 males and 1,927 females; mean age of 62.7 ± 11 years). The goal of the study was to investigate the association between serum bilirubin and subsequent development of cardiovascular death among asymptomatic diabetic patients.

Blood samples were obtained from all patients after an overnight fast of more than 12 hours. Total bilirubin was measured using a Hitachi 7600 chemistry analyzer with a vanadate oxidation method. Lipid profiles including triglycerides, total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL) cholesterol, serum total bilirubin, albumin, creatinine, aspartate transaminase (AST), alanine transaminase (ALT, and glucose were also measured at the same time.

The team followed the patients for 5.4 ± 3.0 years, and there were 218 deaths including 95 cardiovascular deaths. The occurrence of CV death and all-cause death were negatively correlated with increasing serum bilirubin quintiles and actual bilirubin values. Serum bilirubin was negatively associated with incident cardiovascular death and all-cause death. The addition of bilirubin for cardiovascular death increased the C-statistic from 0.713 to 0.729 and showed an integrated discrimination improvement (IDI) of 0.012 with 8.57% improvement in net reclassification analysis.

The authors concluded that higher serum concentrations of bilirubin are associated with a decreased risk of developing CV and all-cause death in diabetic patients. Bilirubin improved the risk prediction of cardiovascular death but provided only a slightly better prediction of all-cause death than conventional risk factors. The study was published in the January 2019 issue of the journal Clinica Chimica Acta.

Related Links:
National Yang-Ming University

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Molecular Diagnostics

view channel
Image: The fastGEN BCR::ABL1 Cancer kit offers a way to personalize treatment strategies for leukemia (Photo courtesy of BioVendor MDx)

First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment

The BCR::ABL1 fusion gene plays a key role in the pathogenesis of several blood cancers, particularly chronic myeloid leukemia (CML). This gene results from a chromosomal translocation that causes constitutive... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The new method is quick and easy, and can also be used by non-medical personnel. (Photo courtesy of Zoratto et al. Advanced Science 2024, edited)

New Blood Test Device Modeled on Leeches to Help Diagnose Malaria

Many individuals have a fear of needles, making the experience of having blood drawn from their arm particularly distressing. An alternative method involves taking blood from the fingertip or earlobe,... Read more